Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Bibliographic Details
Title:	Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
Authors:	Angela Huttner, Claire-Anne Siegrist
Source:	Expert Review of Vaccines, Vol 17, Iss 12, Pp 1105-1110 (2018)
Publisher Information:	Taylor & Francis Group, 2018.
Publication Year:	2018
Collection:	LCC:Internal medicine
Subject Terms:	ebola virus disease, ebola vaccine, rvsv-zebov vaccine, immune response, durability, persistence, seropositivity, Internal medicine, RC31-1245
More Details:	Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Areas covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence. Expert commentary: Persistence of EBOV-GP-specific antibody responses is strong at 2 years – currently the longest post-vaccination interval studied – after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1476-0584 1744-8395 14760584
Relation:	https://doaj.org/toc/1476-0584; https://doaj.org/toc/1744-8395
DOI:	10.1080/14760584.2018.1546582
Access URL:	https://doaj.org/article/9d67f68f2c0b4a8dbe3d234a4dd9fc12
Accession Number:	edsdoj.9d67f68f2c0b4a8dbe3d234a4dd9fc12
Database:	Directory of Open Access Journals

More Details
ISSN:	14760584 17448395
DOI:	10.1080/14760584.2018.1546582
Published in:	Expert Review of Vaccines
Language:	English